Protalix BioTherapeutics (PLX) Share-based Compensation (2010 - 2026)

Protalix BioTherapeutics' Share-based Compensation history runs 17 years deep, the most recent figure standing at $532000.0 for Q1 2026.

• On a quarterly basis, Share-based Compensation rose 1512.12% year-over-year to $532000.0 in Q1 2026; TTM through Mar 2026 was $3.7 million, a 18.84% increase from a year earlier, with the FY2025 full-year figure at $3.2 million, down 2.09% from the prior year.
• Share-based Compensation fell to $532000.0 in Q1 2026 per PLX's latest filing, from $1.6 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $2.9 million in Q4 2024 and bottomed at -$1.6 million in Q3 2024.
• The 5-year median for Share-based Compensation is $335000.0 (2022), against an average of $550625.0.
• Across the five-year window, Share-based Compensation plunged 322.64% in 2024 and jumped 1512.12% in 2026, its largest moves.
• Year by year, Share-based Compensation stood at $398000.0 in 2022, then sank by 229.15% to -$514000.0 in 2023, then soared by 659.73% to $2.9 million in 2024, then plunged by 43.69% to $1.6 million in 2025, then sank by 67.16% to $532000.0 in 2026.
• Per Business Quant, the three latest PLX Share-based Compensation figures stand at $532000.0 (Q1 2026), $1.6 million (Q4 2025), and $1.5 million (Q3 2025).